Doctor-patient relationship management information system:building and application / 中华医院管理杂志

This paper introduced the construction and application of the doctor-patient relationship management information system at a tertiary general hospital in Zigong,and presented a preliminary evaluation of its application effect.On such basis,the authors proposed to enhance medical management capacity with informationization,and motivate medical workers with IT tools.At the national level,a standardized management for medical behaviors should be established,to encourage elevation of medical quality and safety,thus effectively improving the doctor-patient relationship.

Different chemotherapy regimens comparing the efficacy and safety in elderly patients with advanced gastric cancer / 实用医学杂志

Objective To analyze and compare efficacy and safety of different chemotherapy regimens in the treatment of elderly patients with advanced gastric cancer. Methods 60 elderly patients admitted to our hospital with advanced gastric cancer were selected as research subjects , and divided into experimental group and control group depending on the treatment of chemotherapy. The experimental group were treated with Gio oxaliplatin (SOX), and patients in the control group accepted Olivier Elizabeth, leucovorin and fluorouracil (FOLFOX6) treatment. Compare and analyze the efficacy of the two groups after two cycles of therapy. Results By chemotherapy, recent efficiency and disease control rate were not significantly different (P>0.05) between the two groups;and there was also no significant difference in the incidence of adverse reactions,such as adverse reactions, fatigue weakness, gastrointestinal reactions, hand-foot syndrome, oral mucositis (P > 0.05). Conclusion The efficacy was equivalent between FOLFOX6 chemotherapy SOX test group and the control group in the treatment of elderly patients with advanced gastric , and there was no significant difference in the incidence of adverse reactions.

Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer / 中国肺癌杂志

<p><b>BACKGROUND</b>Chemotherapy is a main method for patients with advanced non-small cell lung cancer (NSCLC). NSCLC is usually a drug-resistant neoplasm. Innate or acquired drug-resis-tance contributes to the chief cause for bad effect in the treatment of patients with NSCLC. To search for a new anti-cancer drug becomes a goal of clinical oncologists. The aim of the present study is to evaluate the curative effect and side reactions of IRESSA in the treatment of patients with advanced refractory NSCLC.</p><p><b>METHODS</b>The curative investigation was carried out after 100-day oral IRESSA by a dosage of 250mg/d in patients with advanced refractory NSCLC. The patients had ever experienced at least one regimen of chemotherapy.</p><p><b>RESULTS</b>Totally 33 patients enrolled in this study and all were stage IV. There were 25 males and 8 females. All enrolled patients except one patient who died of severe adverse side reaction completed treatment by IRESSA. Thirty-two cases were evaluated. Complete response was obtained in 1 patient (3.1%). Partial response was seen in 11 patients (34.4%). The overall effective rate was 37.5% (12/32). The disease-control rate was 65.6% (21/32). Time to progression was 5.7 months. Overall survival time was 3.3 to 25.9 months (median survival time was 9.6 months). One-year survival rate was 28.1% (9/32). Two-year survival rate was 6.3% (2/32). The longest survivor lived for 25.9 months. The curative effect was correlated with the pathological type, in sequence of alveolar cell carcinoma, adenocarcinoma and squamous cell carcinoma. Almost all the adverse reactions were acceptable. The main adverse reactions included rash, itching of skin, arthralgia, diarrhea, anorexia, nausea, vomiting, dizziness, headache, chest distress and abdominal pain. No patients showed abnormal in liver or kidney function. No electrocardiogram abnormality was found. One patient who had chronic pulmonary fibrosis before died of respiratory failure due to severe interstitial pneumonia.</p><p><b>CONCLUSIONS</b>IRESSA takes better effect on the advanced drug-resistant patients with NSCLC. So IRESSA may be accepted as third line in the treatment of advanced NSCLC and as first line in the treatment of patients with bad constitution who have no opportinities for operation, irradiation therapy or chemotherapy.</p>

Genealogical Investigation on Patients with Alopecia Areata / 中华皮肤科杂志

In the genealogical investigation into 1210 patients with alopecia areata(AA), we found 75 cases with a positive family history of AA, the familial incidence was 6.2%. The incidence of AA in the 75 families (1093 cases) was 14.91% (163 cases). In these families, there were 142 patients in first-grade relatives of the family members, 17 in second-grade, and 4 in third-grade. We observed 70 cases in 33 families within one generation, 87 cases in 40 families within two succesive generations, and 6 cases in 2 families within three successive generations, four pairs of monozygotic twins appeared in this investigation, but just one of each pair was affected. The relationship between pathogenesis of AA and genetic factor has been discussed.